Chronic hepatitis B

Indication for Interferon, alfa-2b

Population group: Suitable for both men and women, only adults (18 - 65 years old)

For this indication, competent medicine agencies globally authorize below treatments:

5-10 million IU once every other day

Route of admnistration

Subcutaneous

Defined daily dose

5,000,000 - 10,000,000 [iU]

Dosage regimen

From 5,000,000 To 10,000,000 [iU] once every 2 day(s)

Detailed description

The recommended dose is in the range 5 to 10 million IU administered subcutaneously three times a week (every other day) for a period of 4 to 6 months.

The administered dose should be reduced by 50% in case of occurrence of haematological disorders (white blood cells <1,500/mm³, granulocytes <1,000/mm³, thrombocytes <100,000/mm³). Treatment should be discontinued in case of severe leukopaenia (<1,200/mm³), severe neutropaenia (<750/mm³) or severe thrombocytopaenia (<70,000/mm³).

For all patients, if no improvement on serum HBV-DNA is observed after 3 to 4 months of treatment (at the maximum tolerated dose), discontinue interferon alpha-2b therapy.

Active ingredient

Recombinant interferon alfa-2b is a sterile, stable, formulation of highly purified interferon alfa-2b produced by recombinant DNA techniques. Interferons exert their cellular activities by binding to specific membrane receptors on the cell surface. Recombinant interferon alfa-2b has exhibited antiproliferative effects in studies employing both animal and human cell culture systems as well as human tumour xenografts in animals. It has demonstrated significant immunomodulatory activity in vitro.

Read more about Interferon, alfa-2b

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner